Myelodysplastic Syndrome
Original Research
Agent Orange and Myelodysplastic Syndrome: A Single VAMC Experience
Case Reports
A Clonal Complete Remission Induced by IDH1 Inhibitor Ivosidenib in a Myelodysplastic Syndrome (MDS) With Co-Mutations of IDH1 and the ZRSR2 RNA Splicing Gene
Conference Coverage
New mRNA Vaccines in Development for Cancer and Infections
Different forms and designations of mRNA vaccines are used, depending on the application and desired effect.
News
Can a Risk Score Predict Kidney Injury After Cisplatin?
Researchers have developed a risk algorithm to predict acute kidney injury after cisplatin administration and tested it using data from six US...
News
Oncologists Voice Ethical Concerns Over AI in Cancer Care
Researchers ask 204 oncologists from 37 states for their views on the ethical implications of using AI for cancer care.
News
Should Opioids Be Used for Chronic Cancer Pain?
Prescribing strategies are partly driven by peer pressure, new research suggests.
Latest News
ASCO Releases Vaccination Guidelines for Adults With Cancer
Oncologists may be key in ensuring patients with cancer safely receive vaccinations and avert avoidable infections.
News
FDA OKs new agent to block chemotherapy-induced neutropenia
Efbemalenograstim has been approved by the FDA to combat infections in adults being treated for nonmyeloid cancers.
News
Study confirms small blood cancer risk from CT scans
New research suggests that radiation exposure from CT scans heightens the risk of blood cancer in people under age 22.
News
FDA OKs ivosidenib for IDH1-mutated myelodysplastic syndromes
For adults with a rare form of myelodysplastic syndromes, the FDA has approved a targeted therapy called ivosidenib.